Management of elderly patients with chronic myeloproliferative hemopathies
Închide
Conţinutul numărului revistei
Articolul precedent
Articolul urmator
480 5
Ultima descărcare din IBN:
2023-02-15 12:37
Căutarea după subiecte
similare conform CZU
616.155.392.8-036.12-053.9 (1)
Patologia sistemului circulator, a vaselor sanguine. Tulburări cardiovasculare (970)
SM ISO690:2012
MUSTEAŢĂ, Vasile, STRATAN, Valentina, CATRINICI, Larisa, MUSTEAŢĂ, Larisa, DUDNIC, Cristina. Management of elderly patients with chronic myeloproliferative hemopathies. In: Moldovan Medical Journal, 2020, nr. 6(63), pp. 12-15. ISSN 2537-6373. DOI: https://doi.org/10.5281/zenodo.4028363
EXPORT metadate:
Google Scholar
Crossref
CERIF

DataCite
Dublin Core
Moldovan Medical Journal
Numărul 6(63) / 2020 / ISSN 2537-6373 /ISSNe 2537-6381

Management of elderly patients with chronic myeloproliferative hemopathies

DOI: https://doi.org/10.5281/zenodo.4028363
CZU: 616.155.392.8-036.12-053.9

Pag. 12-15

Musteaţă Vasile12, Stratan Valentina2, Catrinici Larisa2, Musteaţă Larisa1, Dudnic Cristina12
 
1 ”Nicolae Testemițanu” State University of Medicine and Pharmacy,
2 Institute of Oncology
 
Disponibil în IBN: 9 decembrie 2020


Rezumat

Background: Chronic myeloproliferative hemopathies (CMPH) as a whole are the most common chronic leukemias in the elderly in the structure of morbidity by hematological malignancies with primary bone marrow involvement, being characterized in the advanced stages by a severe, recurrent evolution and unfavorable prognosis, with negative socio-economic impact. Material and methods: A clinical, analytical, and descriptive study was carried out along with the narrative review of the international literature on the subject. The study enrolled 91 elderly patients with different phases of chronic myeloid leukemia (CML), primary myelofibrosis (PMF) and polycythemia vera (PV), who were followed up and treated at the Institute of Oncology in the period of 1995–2020. According to the impact score, 25 relevant primary sources were identified and selected having a scientific, reproducible and transparent approach to the relevant subject, followed by data extraction and analysis. Results: The overall one- and 5-year survival in patients aged greater than or equal to 60 years old treated with tyrosine kinase inhibitors (TKIs) was 97.6 and 79%, being lower as compared with the same indices in the totality of CML. In elderly PV patients the overall 5-and 10-year survival made up 93.5% and 76.4%, being lesser than registered in all patients with PV. As reported in the recent references, a significant rate of patients with CMPH underwent reduced working hours, discontinued employment, and medical disability: PMF – 38%, 35%, 33%, and PV – 33%, 28%, and 15%, respectively. Conclusions: The long-term treatment results in elderly patients with CMPH fail compared to those in the CMPH totality, due to the development of age-related diseases and vascular accidents caused by leuko- and thrombocytosis.

Cuvinte-cheie
myeloproliferative hemopathies, myeloid leukemia, myelofibrosis, polycythemia vera, elderly patients